{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:26:25Z","timestamp":1768991185315,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.pbb.2021.173183","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T03:27:43Z","timestamp":1616556463000},"page":"173183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys"],"prefix":"10.1016","volume":"205","author":[{"given":"Takeshi","family":"Enomoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Nakako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Goda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2021.173183_bb0005","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/mds.27341","article-title":"A selective phosphodiesterase 10A inhibitor reduces L-dopa-induced dyskinesias in Parkinsonian monkeys","volume":"33","author":"Beck","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2021.173183_bb0010","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2021.173183_bb0015","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1093\/cercor\/bhz041","article-title":"Phosphodiesterase 1 bridges glutamate inputs with NO- and dopamine-induced cyclic nucleotide signals in the striatum","volume":"29","author":"Betolngar","year":"2019","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.pbb.2021.173183_bb0020","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap","volume":"9","author":"Calabresi","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.pbb.2021.173183_bb0025","doi-asserted-by":"crossref","unstructured":"Davis, R., Riesenberg, R., Laskowitz, D., Guptill, J., Sanders, L., Cooney, J., Satlin, A., O'Brien, J., Duthiel, S., Cruz, S., Hendrick, J., Li, P., Wennogle, L., Glass, S., Pinho, M., Taylor, E., Kozauer, S., Weingart, M., Mates, S., Snyder, G., Vanover, K., 2019. ITI-214, a novel phosphodiesterase I inhibitor for the treatment of Parkinson's disease: results from a phase I\/II clinical study. Neurology 92, 15 Supplement P2.8\u2013051.","DOI":"10.1212\/WNL.92.15_supplement.P2.8-051"},{"key":"10.1016\/j.pbb.2021.173183_bb0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40263-018-0498-4","article-title":"Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson\u2019s disease","volume":"32","author":"Elmer","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2021.173183_bb0035","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ilar.48.4.339","article-title":"Nonhuman primate models of Parkinson\u2019s disease","volume":"48","author":"Emborg","year":"2007","journal-title":"ILAR J."},{"key":"10.1016\/j.pbb.2021.173183_bb0040","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1037\/bne0000273","article-title":"Blockade of dopamine D1 receptors, but not D2 receptors, decreases motivation in a novel effort-discounting paradigm in common marmosets","volume":"132","author":"Enomoto","year":"2018","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.pbb.2021.173183_bb0045","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/jpet.119.260869","article-title":"A novel phosphodiesterase 1 inhibitor DSR-141562 exhibits efficacies in animal models for positive, negative, and cognitive symptoms associated with schizophrenia","volume":"371","author":"Enomoto","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173183_bb0050","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","article-title":"Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure","volume":"21","author":"Fox","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2021.173183_bb0055","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.25133","article-title":"A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale","volume":"27","author":"Fox","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2021.173183_bb0060","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1460-9568.2008.06387.x","article-title":"Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms","volume":"28","author":"Giorgi","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2021.173183_bb0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/adt.2008.135","article-title":"Scintillation proximity assays in high-throughput screening","volume":"6","author":"Glickman","year":"2008","journal-title":"Assay Drug. Dev. Technol."},{"key":"10.1016\/j.pbb.2021.173183_bb0070","doi-asserted-by":"crossref","unstructured":"He, J., Kleyman, M., Chen, J., Alikaya, A., Rothenhoefer, K.M., Ozturk, B.E., Wirthlin, M., Fish, K., Byrne, L.C.T., Pfenning, A.R., Stauffer, W.R., 2020. Transcriptional diversity of medium spiny neurons in the primate striatum. bioRxiv - Neuroscience, DOI: https:\/\/doi.org\/10.1101\/2020.10.25.354159.","DOI":"10.1101\/2020.10.25.354159"},{"key":"10.1016\/j.pbb.2021.173183_bb0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2018.02.007","article-title":"Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: clinical overview and translational considerations","volume":"87","author":"Heckman","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2021.173183_bb0080","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-dopa-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pbb.2021.173183_bb0085","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cellsig.2013.10.007","article-title":"Select 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain","volume":"26","author":"Kelly","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.pbb.2021.173183_bb0090","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/mds.25859","article-title":"Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"29","author":"Ko","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2021.173183_bb0095","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173183_bb0100","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.bbapap.2015.01.007","article-title":"Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery","volume":"1854","author":"Lin","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.pbb.2021.173183_bb0105","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00702-018-1846-8","article-title":"Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications","volume":"125","author":"Mellone","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pbb.2021.173183_bb0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00702-017-1722-y","article-title":"Non-human primate models of PD to test novel therapies","volume":"125","author":"Morissette","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pbb.2021.173183_bb0115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.pbb.2021.173183_bb0120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-3-319-58811-7_10","article-title":"Regulation of striatal neuron activity by cyclic nucleotide signaling and Phosphodiesterase inhibition: implications for the treatment of Parkinson\u2019s disease","volume":"17","author":"Padovan-Neto","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"10.1016\/j.pbb.2021.173183_bb0125","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1073\/pnas.89.22.11079","article-title":"Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum","volume":"89","author":"Polli","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2021.173183_bb0130","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1523\/JNEUROSCI.22-12-05188.2002","article-title":"Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning","volume":"22","author":"Reed","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2021.173183_bb0135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fnbeh.2018.00052","article-title":"Dopamine, effort-based choice, and behavioral economics: basic and translational research","volume":"12","author":"Salamone","year":"2018","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2021.173183_bb0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jneumeth.2018.10.037","article-title":"A non-human primate model for stable chronic Parkinson's disease induced by MPTP administration based on individual behavioral quantification","volume":"311","author":"Seo","year":"2019","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.pbb.2021.173183_bb0145","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/TCRM.S144481","article-title":"Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease","volume":"14","author":"Sharma","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.pbb.2021.173183_bb0150","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00213-006-0347-x","article-title":"Differential contributions of dopaminergic D1-like and D2-like receptors to cognitive function in rhesus monkeys","volume":"188","author":"Von Huben","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173183_bb0155","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1523\/JNEUROSCI.14-03-00973.1994","article-title":"Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain","volume":"14","author":"Yan","year":"1994","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2021.173183_bb0160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.pbb.2015.05.003","article-title":"The role of dopamine D1 receptor transmission in effort-related choice behavior: effects of D1 agonists","volume":"135","author":"Yohn","year":"2015","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305721000824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305721000824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:38:28Z","timestamp":1758775108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305721000824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":32,"alternative-id":["S0091305721000824"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2021.173183","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2021.173183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173183"}}